Comparative Pharmacology
Head-to-head clinical analysis: GENTAK versus HUMATIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENTAK versus HUMATIN.
GENTAK vs HUMATIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gentamicin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit of susceptible bacteria, causing misreading of mRNA and inhibiting protein synthesis, leading to bacterial cell death.
Aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of mRNA and production of nonfunctional proteins.
Gentamicin 3-5 mg/kg IV or IM once daily; alternatively, 1.5-2.5 mg/kg IV or IM every 8 hours.
15-25 mg/kg/day orally in 4 divided doses for hepatic coma; 50 mg/kg/day orally in 4 divided doses for infectious diarrhea, max 4 g/day.
None Documented
None Documented
2–3 hours in adults with normal renal function; prolonged to 24–60 hours in severe renal impairment (CrCl <10 mL/min).
2-3 hours (serum half-life of absorbed fraction); clinically negligible due to minimal systemic absorption
Renal excretion of unchanged drug accounts for >90% of elimination; <5% biliary/fecal.
Primarily unchanged in feces (~90%); small amount absorbed is excreted renally as unchanged drug (~1%)
Category C
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic